263 related articles for article (PubMed ID: 17344611)
1. [Measurement of activated clotting time during cardiopulmonary bypass in infective endocarditis patients].
Jiang L; Yu JF
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):167-9. PubMed ID: 17344611
[TBL] [Abstract][Full Text] [Related]
2. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
[TBL] [Abstract][Full Text] [Related]
3. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
J Thorac Cardiovasc Surg; 1983 Feb; 85(2):174-85. PubMed ID: 6823136
[TBL] [Abstract][Full Text] [Related]
4. Monitoring and management of anticoagulation in children requiring extracorporeal circulation.
Malviya S
Semin Thromb Hemost; 1997; 23(6):563-7. PubMed ID: 9469631
[TBL] [Abstract][Full Text] [Related]
5. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.
Akl BF; Vargas GM; Neal J; Robillard J; Kelly P
J Thorac Cardiovasc Surg; 1980 Jan; 79(1):97-102. PubMed ID: 7350393
[TBL] [Abstract][Full Text] [Related]
7. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS
J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
[TBL] [Abstract][Full Text] [Related]
8. The treatment of heparin resistance with Antithrombin III in cardiac surgery.
Kanbak M
Can J Anaesth; 1999 Jun; 46(6):581-5. PubMed ID: 10391608
[TBL] [Abstract][Full Text] [Related]
9. Changing systems for measuring activated clotting times: impact on the clinical practice of heparin anticoagulation during cardiac surgery.
Patteril M; Stafford-Smith M; Toffaletti JG; Bute BP; Milano CA; Welsby IJ
Clin Chim Acta; 2005 Jun; 356(1-2):218-24. PubMed ID: 15936321
[TBL] [Abstract][Full Text] [Related]
10. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery.
Vonk AB; Veerhoek D; van den Brom CE; van Barneveld LJ; Boer C
J Cardiothorac Vasc Anesth; 2014 Apr; 28(2):235-41. PubMed ID: 24342152
[TBL] [Abstract][Full Text] [Related]
11. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
12. Impact of protamine dose on activated clotting time and thromboelastography in infants and small children undergoing cardiopulmonary bypass.
Gautam NK; Schmitz ML; Harrison D; Zabala LM; Killebrew P; Belcher RH; Prodhan P; McKamie W; Norvell DC
Paediatr Anaesth; 2013 Mar; 23(3):233-41. PubMed ID: 23279140
[TBL] [Abstract][Full Text] [Related]
13. Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial.
Arsenault KA; Paikin JS; Hirsh J; Dale B; Whitlock RP; Teoh K; Young E; Ginsberg JS; Weitz JI; Eikelboom JW
J Thorac Cardiovasc Surg; 2012 Oct; 144(4):944-950.e3. PubMed ID: 22743176
[TBL] [Abstract][Full Text] [Related]
14. How much heparin do we really need to go on pump? A rethink of current practices.
Shuhaibar MN; Hargrove M; Millat MH; O'Donnell A; Aherne T
Eur J Cardiothorac Surg; 2004 Nov; 26(5):947-50. PubMed ID: 15519187
[TBL] [Abstract][Full Text] [Related]
15. Management of prekallikrein deficiency during cardiac surgery.
Eeckhoudt SL; Momeni M; Matta A; Latinne D; Arnout J; Hermans C
Thromb Haemost; 2010 Apr; 103(4):866-7. PubMed ID: 20135073
[No Abstract] [Full Text] [Related]
16. Activated clotting time for control of anticoagulation during surgery.
Lefemine AA; Lewis M
Am Surg; 1985 May; 51(5):274-8. PubMed ID: 3994170
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass.
Tao W; Deyo DJ; Brunston RL; Vertrees RA; Grochoske TL; Zwischenberger JB
ASAIO J; 1997; 43(5):M825-30. PubMed ID: 9360162
[TBL] [Abstract][Full Text] [Related]
18. [Heparin monitoring during cardiopulmonary bypass in congenital heart surgery].
Isomatsu Y; Imai Y; Seo K; Terada M; Aoki M; Shin'oka T
Kyobu Geka; 2000 Nov; 53(12):1001-4. PubMed ID: 11079303
[TBL] [Abstract][Full Text] [Related]
19. Safety issues in heparin and protamine administration for extracorporeal circulation.
Jobes DR
J Cardiothorac Vasc Anesth; 1998 Apr; 12(2 Suppl 1):17-20. PubMed ID: 9583571
[TBL] [Abstract][Full Text] [Related]
20. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?
Teoh KH; Young E; Blackall MH; Roberts RS; Hirsh J
J Thorac Cardiovasc Surg; 2004 Aug; 128(2):211-9. PubMed ID: 15282457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
